Changing trends in serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive diseases in central Thailand, 2009-2012

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 7, 2014, Pages 1866-1873

  Phongsamart, Wanatpreeya ^a   Srifeungfung, Somporn ^a   Chatsuwan, Tanittha ^b   Nunthapisud, Pongpun ^c   Treerauthaweeraphong, Vipa ^c   Rungnobhakhun, Pimpha ^d   Sricharoenchai, Sirintip ^a   Chokephaibulkit, Kulkanya ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b QUEEN SIRIKIT NATIONAL INSTITUTE OF CHILD HEALTH   (Thailand)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d Bhumipol Adulyadej Hospital   (Thailand)

Author keywords

Antimicrobial susceptibility; Invasive pneumococcal disease; IPD; PCV; Pneumococcal conjugate vaccine; Serotype; Vaccine coverage

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEFDINIR; CEFDITOREN; CEFOTAXIME; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; OFLOXACIN; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; TETRACYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BREAKTHROUGH INFECTION; CHILD; CONTROLLED STUDY; DISEASE SURVEILLANCE; HUMAN; INFANT; INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NEWBORN; NONHUMAN; PNEUMOCOCCAL INFECTION; REFERENCE VALUE; SEROTYPING; STRAIN DIFFERENCE; STREPTOCOCCUS PNEUMONIAE; THAILAND; TREATMENT PLANNING; TREND STUDY; BACTEREMIA; CLASSIFICATION; DRUG EFFECTS; FEMALE; ISOLATION AND PURIFICATION; MALE; MENINGITIS, BACTERIAL; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; SEROTYPE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MENINGITIS, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; SEROGROUP; STREPTOCOCCUS PNEUMONIAE; THAILAND; YOUNG ADULT;

EID: 84908556003     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.28675     Document Type: Article

References (49)

1. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, et al.; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32-41; PMID:19947881; http://dx.doi.org/10.1086/648593
2. Bettinger JA, Scheifele DW, Kellner JD, Halperin SA, Vaudry W, Law B, Tyrrell G; Canadian Immunization Monitoring Program, Active (IMPACT). The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine 2010; 28:2130-6; PMID:20044050; http://dx.doi.org/10.1016/j.vaccine.2009.12.026
3. van der Linden M, Reinert RR, Kern WV, Imöhl M. Epidemiology of serotype 19A isolates from invasive pneumococcal disease in German children. BMC Infect Dis 2013; 13:70; PMID:23384407; http://dx.doi.org/10.1186/1471-2334-13-70
4. Ingels H, Rasmussen J, Andersen PH, Harboe ZB, Glismann S, Konradsen H, Hoffmann S, Valentiner-Branth P, Lambertsen L; Danish Pneumococcal Surveillance Collaboration Group 2009-2010. Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme. Vaccine 2012; 30:3944-50; PMID:22504662; http://dx.doi.org/10.1016/j.vaccine.2012.03.060
5. de Sevilla MF, García-García JJ, Esteva C, Moraga F, Hernández S, Selva L, Coll F, Ciruela P, Planes AM, Codina G, et al. Clinical presentation of invasive pneumococcal disease in Spain in the era of heptavalent conjugate vaccine. Pediatr Infect Dis J 2012; 31:124-8; PMID:22173137; http://dx.doi.org/10.1097/INF.0b013e318241d09e
6. Lepoutre A, Varon E, Georges S, Gutmann L, Lévy-Bruhl D. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro Surveill 2008; 13(35): pii: 18962; PMID:18761883
7. Thomas MF, Sheppard CL, Guiver M, Slack MP, George RC, Gorton R, Paton JY, Simmister C, Cliff D, Elemraid MA, et al. Emergence of pneumococcal 19A empyema in UK children. Arch Dis Child 2012; 97:1070-2; PMID:23076341; http://dx.doi.org/10.1136/archdischild-2012-301790
8. Williams SR, Mernagh PJ, Lee MH, Tan JT. Changing epidemiology of invasive pneumococcal disease in Australian children after introduction of a 7-valent pneumococcal conjugate vaccine. Med J Aust 2011; 194:116-20; PMID:21299484
9. Bautista-Márquez A, Richardson V, Ortiz-Orozco O, Luna-Cruz ME, Carnalla-Barajas MN, Echaniz-Avilés G, Bobadilla-del Valle M, Martínez-Medina L, Montalvo-Vázquez AM, de la Re-Montaño N, et al. Prevalence of pneumococcal disease, serotype distribution, and antimicrobial susceptibility in Mexican children younger than 5 years of age. Arch Med Res 2013; 44:142-50; PMID:23291380; http://dx.doi.org/10.1016/j.arcmed.2012.12.005
10. Thoon KC, Chong CY, Tee NW. Early impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in Singapore children, 2005 through 2010. Int J Infect Dis 2012; 16:e209-15; PMID:22281191; http://dx.doi.org/10.1016/j.ijid.2011.11.014
11. Liao WH, Lin SH, Lai CC, Tan CK, Liao CH, Huang YT, Wang CY, Hsueh PR. Impact of pneumococcal vaccines on invasive pneumococcal disease in Taiwan. Eur J Clin Microbiol Infect Dis 2010; 29:489-92; PMID:20108017; http://dx.doi.org/10.1007/s10096-010-0873-7
12. Choi EH, Kim SH, Eun BW, Kim SJ, Kim NH, Lee J, Lee HJ. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 2008; 14:275-81; PMID:18258121; http://dx.doi.org/10.3201/eid1402.070807
13. Steenhoff AP, Shah SS, Ratner AJ, Patil SM, McGowan KL. Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia. Clin Infect Dis 2006; 42:907-14; PMID:16511752; http://dx.doi.org/10.1086/500941
14. Pelton SI, Huot H, Finkelstein JA, Bishop CJ, Hsu KK, Kellenberg J, Huang SS, Goldstein R, Hanage WP. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007; 26:468-72; PMID:17529860; http://dx.doi.org/10.1097/INF.0b013e31803df9ca
15. Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 2007; 26:123-8; PMID:17259873; http://dx.doi.org/10.1097/01.inf.0000253059.84602.c3
16. Gertz RE Jr., Li Z, Pimenta FC, Jackson D, Juni BA, Lynfield R, Jorgensen JH, Carvalho MdaG, Beall BW; Active Bacterial Core Surveillance Team. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J Infect Dis 2010; 201:770-5; PMID:20178139; http://dx.doi.org/10.1086/650496
17. Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsène JP, Lommel P, Dieussaert I, Schuerman L. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009; 28(Suppl):S66-76; PMID:19325449; http://dx.doi.org/10.1097/INF.0b013e318199f8ef
18. Prymula R, Schuerman L. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev Vaccines 2009; 8:1479-500; PMID:19863240; http://dx.doi.org/10.1586/erv.09.113
19. Centers for Disease Control and Prevention (CDC). Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010; 59:258-61; PMID:20224542
20. Skinner JM, Indrawati L, Cannon J, Blue J, Winters M, Macnair J, Pujar N, Manger W, Zhang Y, Antonello J, et al. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. Vaccine 2011; 29:8870-6; PMID:21964055; http://dx.doi.org/10.1016/j.vaccine.2011.09.078
21. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.). Emerg Infect Dis 2013; 19:1074-83; PMID:23763847; http://dx.doi.org/10.3201/eid1907.121830
22. Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N, Porat N, Gurtman A, Gruber WC, Scott DA. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis 2013; 57:952-62; PMID:23804191; http://dx.doi.org/10.1093/cid/cit428
23. Jauneikaite E, Jefferies JM, Hibberd ML, Clarke SC. Prevalence of Streptococcus pneumoniae serotypes causing invasive and non-invasive disease in South East Asia: a review. Vaccine 2012; 30:3503-14; PMID:22475858; http://dx.doi.org/10.1016/j.vaccine.2012.03.066
24. Kim SH, Song JH, Chung DR, Thamlikitkul V, Yang Y, Wang H, Lu M, So TM, Hsueh PR, Yasin RM, et al.; ANSORP Study Group. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Antimicrob Agents Chemother 2012; 56:1418-26; PMID:22232285; http://dx.doi.org/10.1128/AAC.05658-11
25. Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis 2009; 199:776-85; PMID:19434927; http://dx.doi.org/10.1086/597044
26. Phongsamart W, Srifeungfung S, Dejsirilert S, Chatsuwan T, Nunthapisud P, Treerauthaweeraphong V, Rungnobhakhun P, Chokephaibulkit K. Serotype distribution and antimicrobial susceptibility of S. pneumoniae causing invasive disease in Thai children younger than 5 years old, 2000-2005. Vaccine 2007; 25:1275-80; PMID:17092618; http://dx.doi.org/10.1016/j.vaccine.2006.10.001
27. Srifeungfung S, Tribuddharat C, Comerungsee S, Chatsuwan T, Treerauthanaweeraphong V, Rungnobhakhun P, Nunthapisud P, Chokephaibulkit K. Serotype coverage of pneumococcal conjugate vaccine and drug susceptibility of Streptococcus pneumoniae isolated from invasive or non-invasive diseases in central Thailand, 2006-2009. Vaccine 2010; 28:3440-4; PMID:20199759; http://dx.doi.org/10.1016/j.vaccine.2010.02.071
28. Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007. MMWR Morb Mortal Wkly Rep 2010; 59:253-7; PMID:20224541
29. Liu Y, Wang H, Chen M, Sun Z, Zhao R, Zhang L, Wang H, Zhang H, Wang L, Chu Y, et al. Serotype distribution and antimicrobial resistance patterns of Streptococcus pneumoniae isolated from children in China younger than 5 years. Diagn Microbiol Infect Dis 2008; 61:256-63; PMID:18358662; http://dx.doi.org/10.1016/j.diagmicrobio.2008.02.004
30. Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 2010; 28:4249-59; PMID:20416266; http://dx.doi.org/10.1016/j.vaccine.2010.04.020
31. Dejsirilert S. Thai IBIS 2010-2012: What did we learn? What's next? Thai-IBIS Plus Workshop, July 31 - August 1, 2012, Cha-am, Phetchaburi, Thailand. (accessed Jul 25, 2013). Available from http://narst.dmsc.moph.go.th/files-nw/IBISWorkshop31July2012/IBISWorkshop31July2012-ThaiIBIS%202010-2012%20by%20Surang%2030Jul2012%20(1).pdf.
32. Pichon B, Ladhani SN, Slack MP, Segonds-Pichon A, Andrews NJ, Waight PA, Miller E, George R. Changes in molecular epidemiology of streptococcus pneumoniae causing meningitis following introduction of pneumococcal conjugate vaccination in England and Wales. J Clin Microbiol 2013; 51:820-7; PMID:23269742; http://dx.doi.org/10.1128/JCM.01917-12
33. Ampofo K, Pavia AT, Chris S, Hersh AL, Bender JM, Blaschke AJ, Weng HY, Korgenski KE, Daly J, Mason EO, et al. The changing epidemiology of invasive pneumococcal disease at a tertiary children's hospital through the 7-valent pneumococcal conjugate vaccine era: a case for continuous surveillance. Pediatr Infect Dis J 2012; 31:228-34; PMID:22330164; http://dx.doi.org/10.1097/INF.0b013e31823dcc72
34. Centers for Disease Control and Prevention (CDC). Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR Morb Mortal Wkly Rep 2012; 61:394-5; PMID:22647745
35. Srifuengfung S, Phongsamart W, Tribuddharat C, Chatsuwan T, Rungnobhakhun P, Sapcharoen S, Chokephaibulkit K. Serotype distribution and antibiotic susceptibility of invasive Streptococcus pneumoniae isolates in patients aged 50 years or older in Thailand. Hum Vaccin Immunother 2013; 10: (Forthcoming); PMID:24030588
36. Liu Z, Nachamkin I, Edelstein PH, Lautenbach E, Metlay JP. Serotype emergence and genotype distribution among macrolide-resistant invasive Streptococcus pneumoniae isolates in the postconjugate vaccine (PCV-7) era. Antimicrob Agents Chemother 2012; 56:743-50; PMID:22123697; http://dx.doi.org/10.1128/AAC.05122-11
37. Gant CM, Rosingh AW, López-Hontangas JL, van der Heijden M, González-Morán F, Bijlsma JJ, Canton E; RedMiva (Network of Microbiological Vigilance of Comunidad Valenciana). Serotype distribution and antimicrobial resistance of invasive pneumococcal disease strains in the Comunidad Valenciana, Spain, during the winter of 2009-2010: low PCV7 coverage and high levofloxacin resistance. Antimicrob Agents Chemother 2012; 56:4988-9; PMID:22751535; http://dx.doi.org/10.1128/AAC.01201-12
38. Shibl AM, Memish ZA, Al-Kattan KM. Antibiotic resistance and serotype distribution of invasive pneumococcal diseases before and after introduction of pneumococcal conjugate vaccine in the Kingdom of Saudi Arabia (KSA). Vaccine 2012; 30(Suppl 6):G32-6; PMID:23228355; http://dx.doi.org/10.1016/j.vaccine.2012.07.030
39. Lee MY, Ko KS, Oh WS, Park S, Lee JY, Baek JY, Suh JY, Peck KR, Lee NY, Song JH. In vitro activity of cefditoren: antimicrobial efficacy against major respiratory pathogens from Asian countries. Int J Antimicrob Agents 2006; 28:14-8; PMID:16777383; http://dx.doi.org/10.1016/j.ijantimicag.2006.02.014
40. Soriano F, Giménez MJ, Aguilar L. Cefditoren in upper and lower community-acquired respiratory tract infections. Drug Des Devel Ther 2011; 5:85-94; PMID:21340042; http://dx.doi.org/10.2147/DDDT.S9499
41. Stefani S, Mezzatesta ML, Fadda G, Mattina R, Palù G, Rossano F, Tufano MA, Schito GC, Nicoletti G. Antibacterial activity of cefditoren against major community-acquired respiratory pathogens recently isolated in Italy. J Chemother 2008; 20:561-9; PMID:19028617; http://dx.doi.org/10.1179/joc.2008.20.5.561
42. Fritsche TR, Biedenbach DJ, Jones RN. Update of the activity of cefditoren and comparator oral beta-lactam agents tested against community-acquired Streptococcus pneumoniae isolates (USA, 2004-2006). J Chemother 2008; 20:170-4; PMID:18467241; http://dx.doi.org/10.1179/joc.2008.20.2.170
43. Cafini F, Aguilar L, Alou L, Giménez MJ, Sevillano D, Torrico M, González N, Granizo JJ, Martín-Herrero JE, Prieto J. Cidal activity of oral thirdgeneration cephalosporins against Streptococcus pneumoniae in relation to cefotaxime intrinsic activity. Eur J Clin Microbiol Infect Dis 2008; 27:679-83; PMID:18299905; http://dx.doi.org/10.1007/s10096-008-0493-7
44. Moore MR, Gertz RE Jr., Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, Gershman K, Reingold A, Farley M, Harrison LH, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008; 197:1016-27; PMID:18419539; http://dx.doi.org/10.1086/528996
45. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Beekmann SE, Doern GV. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin Infect Dis 2009; 48:e23-33; PMID:19115971; http://dx.doi.org/10.1086/595857
46. Tsai HY, Chen YH, Liao CH, Lu PL, Huang CH, Lu CT, Chuang YC, Tsao SM, Chen YS, Liu YC, et al. Trends in the antimicrobial susceptibilities and serotypes of Streptococcus pneumoniae: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006-2010. Int J Antimicrob Agents 2013; 42:312-6; PMID:23849332; http://dx.doi.org/10.1016/j.ijantimicag.2013.05.013
47. Spellerberg B, Brandt C. Streptococcus. In: Versalovic J, Carroll KC, Funke G, editors. Manual of Clinical Microbiology, 10th ed. Washington, D.C., USA: ASM Press; 2011. p. 331-49.
48. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial and susceptibility testing: 23rd Informational Supplement (M100-S23). Wayne, PA: Clinical and Laboratory Standards Institute; 2013. Available from: http://xa.yimg.com/kq/groups/17358357/1823053181/name/CLSI%202013%20M100-S23.pdf
49. Harboe ZB, Valentiner-Branth P, Ingels H, Rasmussen JN, Andersen PH, Bjerre CC, Goldblatt D, Ashton L, Haston M, Konradsen HB, et al.; Danish Pneumococcal Surveillance Collaborating Group. Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark. PLoS One 2013; 8:e51460; http://dx.doi.org/10.1371/journal.pone.0051460; PMID:23365635